Complete Freund’s adjuvant as a confounding factor in multiple sclerosis research

2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Complete Freund’s adjuvant (CFA) is used as a standard adjuvant for the induction of experimental autoimmune encephalomyelitis (EAE), the most commonly used animal model in multiple sclerosis studies. Still, CFA induces glial activation and neuroinflammation on its own and provokes pain. In addition, as CFA contains Mycobacteria, an immune response against bacterial antigens is induced in parallel to the response against central nervous system antigens. Thus, CFA can be considered as a confounding factor in multiple sclerosis–related studies performed on EAE. Here, we discuss the effects of CFA in EAE in detail and present EAE variants induced in experimental animals without the use of CFA. We put forward CFA-free EAE variants as valuable tools for studying multiple sclerosis pathogenesis and therapeutic approaches.

References Powered by Scopus

This article is free to access.

Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lazarević, M., Stanisavljević, S., Nikolovski, N., Dimitrijević, M., & Miljković, Đ. (2024). Complete Freund’s adjuvant as a confounding factor in multiple sclerosis research. Frontiers in Immunology. Frontiers Media SA. https://doi.org/10.3389/fimmu.2024.1353865

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

100%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 1

25%

Biochemistry, Genetics and Molecular Bi... 1

25%

Immunology and Microbiology 1

25%

Engineering 1

25%

Save time finding and organizing research with Mendeley

Sign up for free